Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21111351 | 0.72 | CA2 (0.46) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL25485069 | 0.72 | GABRA1 (0.31) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL17616519 | 0.71 | CA2 (0.30) | CA2 | |
| SCHEMBL27102080 | 0.68 | CA2 (0.39) | GABRA1GABRB2CA2KIF11 | |
| SCHEMBL12411501 | 0.65 | MEN1 (0.55) | CA2KIF11 | |
| SCHEMBL24604798 | 0.65 | MEN1 (0.41) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL16185334 | 0.65 | GABRA1 (0.47) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL16282370 | 0.65 | KDM4E (0.40) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL15852947 | 0.64 | CA2 (0.38) | GABRA1GABRB2CA2KIF11PRKDC | |
| SCHEMBL20650336 | 0.64 | CA2 (0.38) | GABRA1GABRB2CA2KIF11PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | GABRA1 3957/4885GABRB2 3758/4885CA2 3870/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | GABRA1 4103/4885GABRB2 4408/4885CA2 4656/4885 |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | GABRA1 3957/4885GABRB2 3758/4885CA2 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.